Medical devices to treat or inhibit restenosis
First Claim
1. An implantable medical device for the treatment or inhibition of restenosis coated with a PPAR agonist selected from the group consisting of netoglitazone, tesaglitazar, and pharmaceutically acceptable derivatives thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain antiproliferative agents, particularly certain PPAR agonists, are disclosed. The anti-restenotic PPAR agonists are netoglitazone, tesaglitazar, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the PPAR agonist with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-PPAR agonist blends are disclosed. Additionally, medical devices having a coating comprising at least one PPAR agonist in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.
110 Citations
16 Claims
- 1. An implantable medical device for the treatment or inhibition of restenosis coated with a PPAR agonist selected from the group consisting of netoglitazone, tesaglitazar, and pharmaceutically acceptable derivatives thereof.
- 5. An intravascular stent for site-specific, controlled-release delivery of a medicament for the treatment of restenosis, said stent having a coating comprising a biocompatible polymer and a PPAR agonist selected from the group consisting of netoglitazone, tesaglitazar and pharmaceutically acceptable derivatives thereof.
-
11. A method of treating or inhibiting restenosis comprising:
-
providing an intravascular stent having a coating comprising a PPAR agonist selected from the group consisting of netoglitazone, tesaglitazar and pharmaceutically acceptable derivatives thereof; and
implanting said intravascular stent into a blood vessel lumen at risk for restenosis wherein said PPAR agonist is released into tissue adjacent said blood vessel lumen in a controlled-release manner. - View Dependent Claims (12)
-
-
13. A method for producing a medical device comprising:
-
providing medical device to be coated;
compounding netoglitazone or tesaglitazar or a pharmaceutically acceptable derivative thereof with a carrier compound; and
coating said medical device with said netoglitazone or tesaglitazar or pharmaceutically acceptable derivative thereof compounded with said carrier compound. - View Dependent Claims (14, 15, 16)
-
Specification